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Abstract
Background: Friedreich ataxia (FRDA) is the most common form of hereditary ataxia characterized by the presence of a GAA
trinucleotide repeat expansion within the first intron of the FXN gene. The expansion inhibits FXN gene expression resulting
in an insufficiency of frataxin protein.
Methodology/Principal Finding: In this study, computational analyses were performed on the 21.3 kb region upstream of
exon 1 of the human FXN gene and orthologs from other species in order to identify conserved non-coding DNA sequences
with potential regulatory functions. The conserved non-coding regions identified were individually analyzed in two
complementing assay systems, a conventional luciferase reporter system and a novel Bacterial Artificial Chromosome (BAC)-
based genomic reporter. The BAC system allows the evaluation of gene expression to be made in the context of its entire
genomic locus and preserves the normal location and spacing of many regulatory elements which may be positioned over
large distances from the initiation codon of the gene.
Conclusions/Significance: The two approaches were used to identify a region of 17 bp located approximately 4.9 kb
upstream of the first exon of the FXN gene that plays an important role in FXN gene expression. Modulation of FXN gene
expression was found to be mediated by the action of the Oct-1 transcription factor at this site. A better understanding of
cis-acting regulatory elements that control FXN gene expression has the potential to develop new strategies for the
upregulation of the FXN gene as a therapy for FRDA.
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Introduction
Friedreich ataxia (FRDA) is an autosomal recessive disorder
characterized by neurodegeneration and cardiomyopathy. It is the
most common form of hereditary ataxia with an estimated 2–3
affected individuals per 100,000 in European populations [1] and
an estimated carrier frequency of 1 in 110 [2–4]. The causative
gene, FXN, is located on the long arm of chromosome 9 (9q13-
21.1). The FXN gene encodes the mitochondrial protein frataxin,
which plays an important role in iron-sulfur cluster biogenesis
[5,6]. Homozygosity for a GAA trinucleotide repeat expansion
within the first intron of the FXN gene is the most common cause
of FRDA. Normal alleles contain 6–34 uninterrupted GAA
repeats. The majority of individuals with FRDA have between
67 to over 1,300 GAA repeats in both FXN alleles. The non-
translated GAA repeat expansion results in inhibition of gene
expression and an insufficiency of frataxin.
An inverse correlation exists between the size of the smaller
expanded allele and transcript levels, the amount of residual
frataxin produced and the age of onset of disease symptoms.
Heterozygous carriers of a GAA repeat expansion produce about
half the normal level of frataxin and are asymptomatic. As the
GAA repeat expansion mutation does not alter the coding
sequence of the gene, it is hypothesized that any increase in
frataxin levels should prove beneficial, while a several-fold increase
could be sufficient to halt disease progression.
There is currently limited information on the regulation of the
FXN gene. The 1,255 bp region upstream of the FXN coding
region contains the minimal promoter. The region is rich in
repetitive elements which appear to be important in promoter
activity. A TATA box is not apparent and Inr/DPE-like elements
found in the vicinity of the transcription start site are not required
for gene expression [7]. A putative E-box and Mt binding site
within the first intron were shown to contribute to FXN promoter
activity [8]. Transcription factors SRF and TFAP2 have been
shown to bind sequences in the promoter and to enhance FXN
expression [9]. There is evidence that the GAA repeat expan-
sion generates a heterochromatin-mediated gene silencing effect
[10,11]. Changes in both DNA methylation and histone
modification have been described [8,10,12–15]. The mechanism
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FXN gene is not known. A recent report hypothesizes that CTCF
depletion and antisense transcription in the 59UTR of the FXN
gene is associated with epigenetic silencing [16]. There is currently
no data on the position of any long-range, cis-acting regulatory
sequences or of associated transcription factors that may control
FXN gene expression.
A better understanding of how cis-acting, long-range regulatory
control elements surrounding the human FXN gene, and the trans-
acting protein factors that act upon them, are responsible for gene
expression in healthy and affected individuals, has the potential to
lead to the development of new strategies that target the
upregulation of the FXN gene as a therapy for FRDA [17]. We
performed comparative genomic analysis of the 21.3 kb region
upstream of the first exon of the human FXN gene and 16
orthologs from other species to identify conserved non-coding
DNA sequences with potential regulatory functions. The con-
served non-coding regions were individually analyzed in two assay
systems, a conventional small plasmid luciferase reporter system
and a novel Bacterial Artificial Chromosome (BAC)-based
genomic reporter. The latter system permits the evaluation of
gene expression to be made in the context of its entire genomic
locus and preserves the normal location and spacing of many
regulatory elements that may be positioned over large distances in
the surrounding chromosomal region. We have identified a
minimal region of 17 bp, located approximately 4.9 kb upstream
of the first exon of the FXN gene that plays an important role in
normal FXN gene expression. Computational methods identified a
number of putative transcription factor sites within this sequence,
of which the Oct-1 transcription factor was found to influence
FXN gene expression via this site.
Results
Bioinformatic identification of conserved non-coding
DNA sequences upstream of the FXN gene
The FXN gene is located on the long arm of chromosome 9.
Our particular focus was on the region upstream of the FXN gene
coding region, specifically the 21.3 kb intergenic region between
the FXN and PRKACG genes. Identification of regions that may
contain potential long-range, cis-acting regulatory elements
controlling the expression of the human FXN gene was achieved
by examining comparative genomic and regulatory data available
on the UCSC Genome Browser [18,19] (Fig. 1A). Comparative
genomic data that was utilized consisted of conserved elements
predicted from multiple alignments by a phylogenetic hidden
Markov model [20–23]. Regulatory data utilized consisted of
regulatory potential (RP) scores computed from alignments of
human, chimpanzee, macaque, mouse, rat, dog and cow [24,25].
The RP score compares frequencies of short alignment patterns
between known regulatory elements and neutral DNA (24,25). RP
scores represent a mixture of conservation, composition and short
pattern structure information gathered from alignments to suggest
the position of new putative regulatory elements. RP scores have
been shown to effectively discriminate regulatory from neutral
DNA stretches [26].
The region upstream of FXN was further investigated for the
presence of conserved regulatory elements including transcription
factor binding sites [27]. Eight highly conserved regions were
identified upstream of exon 1 of the FXN gene (Fig. 1B). The
conserved regions are within a size range of 36 bp to 743 bp and
each harbors homology of 40% to greater than 70% among the
species, and is surrounded by otherwise divergent sequences (data
not shown).
Construction and characterization of a dual reporter
bacterial artificial chromosome
Key control regions can be located large distances from the
genes that they regulate and the normal location and spacing of
many regulatory elements is crucial to facilitate physiological gene
expression patterns. Genomic reporters, in which a reporter fusion
is made to a gene in the context of its entire genomic locus on a
Bacterial Artificial Chromosome (BAC) clone, preserve the
positional relationships of regulatory elements in the surrounding
chromosomal region, and facilitate the recapitulation of normal
gene expression patterns.
We previously identified a 188 kb BAC clone (RP11-265B8)
containing exons 1–5b of the human FXN locus and extensive
flanking regions [28]. The genomic insert is able to successfully
complement the embryonic lethal phenotype of homozygous Fxn
knockout mice, indicating that key regulatory elements required
for normal expression of the FXN gene are present within this
clone [29]. Homologous recombination was used to introduce an
EGFP-Kan/Neo cassette in-frame immediately following the last
codon of exon 5a of the FXN gene (designated RP11-265B8::Ex5-
aEK) [28]. This construct encodes a frataxin-EGFP fusion protein
that is expressed via the endogenous FXN promoter and under the
control of regulatory elements surrounding the intact FXN locus.
The RP11-265B8::Ex5a-EK clone can only be maintained in
bacterial cells but is suitable for transient transfection studies in
eukaryotic cells. In regulatory studies utilizing small reporter
constructs, a second reporter plasmid is typically co-transfected as
a transfection control. Due to their large size, the transfection
efficiency of BAC clones into mammalian cells is usually very low
(around 1–10% depending on the size of the BAC clone and the
cell line being transfected). Co-transfection of a small reporter
plasmid would not be an accurate reflection of the BAC
transfection efficiency, while co-transfection of a second BAC
with a different reporter would prove technically challenging. To
overcome this limitation, a second, independently expressed
DsRed-Express reporter was introduced into the backbone of
the RP11-265B8::Ex5a-EK clone. The chloramphenicol-resis-
tance gene was replaced by the DsRed-Express reporter and an
ampicillin-resistance gene. DsRed-Express has distinct emission
spectra from EGFP and has been optimized for use in mammalian
cells. The independent expression of the DsRed-Express gene
serves as an internal control for transfection efficiency and vector
copy number. Two fluorescent markers allows simultaneous
monitoring of the effects of deleting putative FXN regulatory
elements and the correction for any differences in transfection
efficiencies. The integrity of the new RP11-265B8::Ex5a-EK-
DsAmp (Dual Reporter) construct was confirmed by PCR and
restriction enzyme digestion. The expression of EGFP and DsRed-
Express was confirmed in the transient transfection assay in
BHK21 cells (data not shown).
Construction and characterization of BAC dual reporter
deletion constructs
Each of the eight identified conserved non-coding regions was
individually deleted in the context of the RP11-265B8::Ex5a-EK-
DsAmp (Dual Reporter) construct. Each conserved region was
substituted with a chloramphenicol-resistance gene flanked by
FRT sites via homologous recombination. The chloramphenicol-
resistance gene was subsequently removed of using Flp recombi-
nase to leave a single FRT site in place of the conserved region. It
was not always possible to design homology arms of the targeting
cassette to precisely delete all of the conserved sequences due to
the presence of repetitive elements or lack of unique sequences
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some additional flanking sequence was also removed (Fig. 1B). The
integrity of the required constructs was verified by assessing
chloramphenicol-sensitivity and by PCR and restriction digest
analyses.
In order to investigate the effect of the deletion of each
conserved non-coding region on FXN gene expression, each
construct was analyzed in transient transfection assays in a
mammalian cell line. We have previously shown that the BHK-21
(baby hamster kidney) cell line is readily transfectable with large
DNA constructs and suitable for the in vivo characterization of FXN
gene expression [28].
The EGFP/DsRed-Express ratio produced by the BAC con-
taining a deletion of conserved region 1 was significantly lower
(p=0.0001) than the unmodified control RP11-265B8::Ex5a-EK-
DsAmp (Dual Reporter) construct (Fig. 2). The deletion of
conserved region 6 also resulted in significantly lower FXN gene
expression (p=0.0004). The deletion of conserved region 7 caused
a reduction in expression (p=0.01), but not to the same extent as
deletion of conserved regions 1 and 6. In contrast, the removal of
Figure 1. Cross species sequence comparison. Analysis of cross species sequence comparison of the upstream non-coding region of the FXN
gene utilizing data from the UCSC Genome Browser using the March 2006 (NCBI36/hg18) assembly (http://genome.cse.ucsc.edu). (A) The position of
the human FXN gene on chromosome 9 is shown. The BLASTZ track shows the BLASTZ alignment of human FXN and the mouse Fxn genes. BlastZ
alignments were taken from GenomeTraFaC [27]. The genomic sequences with flanking (upstream to 59 and downstream to 39) 40 kb base pairs of
more than 12,000 human and mouse orthologous gene pairs that had a validated RefSeq ID from the Reference Sequence data of NCBI were
downloaded from the UCSC Genome Browser (Human May 2004 and March 2006 assemblies, and Mouse August 2005 and February 2006
assemblies). Sequence alignment was done using the BlastZ algorithm of PipMaker. The location of each conserved non-coding region identified
upstream of the human FXN gene is shown. The 76regulatory potential (ESPERR Regulatory Potential) displays the regulatory potential (RP) scores
computed from alignment of human, chimpanzee, macaque, mouse, rat, dog, and cow. The peaks illustrate the position of sequences conserved
between the human FXN gene and orthologs in each of the individual species. The PhastCons track shows predictions of conserved elements
produced by the PhastCons program, which identifies conserved elements given a multiple alignment and a hidden Markov model [20]. Both the
ESPERR and PhastCons tracks were obtained from the UCSC Genome Browser [18]. (B) The location (UCSC Genome Browser, Human March 2006
assembly) and size of eight highly conserved regions located upstream of exon 1 of the FXN gene are shown. The size of the deletion encompassing
each conserved region made in the RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter) construct is indicated.
doi:10.1371/journal.pone.0022001.g001
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(p=0.02 and p=0.03, respectively).
EGFP and DsRed-Express expression from each of the BAC
dual-reporter deletion constructs was also analyzed by fluores-
cence microscopy. Supporting the flow cytometry data, a clear
reduction in EGFP expression was observed in cells transfected
with the BAC clones containing a deletion of either conserved
region 1 or 6 (Fig. S1). Deletion of conserved region 7 also
demonstrated lower EGFP expression although not to the same
extent as in the constructs containing deletions of conserved
regions 1 and 6 (Fig. S1).
Analysis of the effects of upstream conserved
non-coding regions on the FXN promoter
To complement the data obtained using the genomic reporter
assay, the examination of FXN gene regulatory mechanisms was
also assessed using small plasmid luciferase reporter constructs. A
set of progressively longer, DNA fragments containing the
endogenous human FXN promoter and one or multiple conserved
non-coding regions was amplified by PCR and cloned into the
pGL3-Basic vector (Fig. 3).
The set of pGL3-Basic derivative constructs containing the FXN
promoter and one or multiple conserved non-coding regions were
separately transfected into two mammalian cell lines, HeLa
(cervical cancer) and BE(2)-M17 (neuroblastoma).
In both cell lines, the construct containing the shortest insert
(1,269 bp region immediately upstream of exon 1 of the FXN gene)
elicited much higher levels of luciferase expression than the
unmodified pGL3-Basic vector without an insert (Fig. 4). These
results support the findings of Greene et. al. [7] that this region
contains the minimal FXN promoter. In the HeLa cell line, the
next longest insert containing 4,923 bp of DNA but excluding any
of the identified conserved regions, produced a similar level of
expression. All of the other constructs, which contained an insert
longer than 5,577 bp, produced a statistically significant increase
in expression compared to that with the shortest insert. The
greatest level of induction (over 2.5-fold) was seen with the
construct that contained the 5,577 bp insert, which includes only
conserved region 1. This result indicates that the presence of
conserved region 1 plays a role in inducing the expression of the
FXN gene, and which was only modestly modified in the presence
of the other conserved regions. In the BE(2)-M17 cell line, a
greater variation was observed in the effects on FXN gene
expression depending on the conserved regions present in each
construct (Fig. 4). Increased or reduced expression was observed
depending on the length of the insert and presumably the presence
of particular conserved regions. This could possibly be attributed
to interactions between positive and negative regulatory roles of
the different conserved regions in this particular cell line.
Nonetheless, in accordance with the findings in the HeLa cell
line, the construct that contained the 5,577 bp insert, which
includes only conserved region 1, led to increased expression in the
BE(2)-M17 cell line, albeit to a lesser extent than in HeLa cells.
As these results indicated that conserved region 1 harbors an
important regulatory element that influences the expression of the
FXN gene, subsequent experiments focused on refining the specific
sequence(s) within this region responsible for the observed effects.
Location of a regulatory element within conserved
region 1
In order to delineate the location of a regulatory element within
conserved region 1, a series of truncated constructs was generated.
The initial focus was on the region located between 4,923 and
5,577 bp upstream of exon 1 of the FXN gene. Three PCR
products were amplified with 59 ends terminating at 5,023, 5,123
and 5,443 bp upstream of exon 1.
The three new constructs (designated pGL3-Basic::5023, pGL3-
Basic::5123 and pGL3-Basic::5443) were transfected into HeLa
and BE(2)-M17 cell lines. For this series of experiments, the
normalized expression of the pGL3-Basic derivative constructs was
compared to the construct containing the 5,577 bp fragment
(pGL3-Basic::5577).
The patterns of expression of all the constructs were very similar
in both the HeLa and BE(2)-M17 cell lines. The new constructs
Figure 2. Expression analysis of BAC dual-reporter deletion constructs. BHK-21 cells were transfected with the RP11-265B8::Ex5a-EK-DsAmp
(Dual Reporter) construct and derivatives individually containing deletions of the identified conserved non-coding regions. EGFP and DsRed-Express
expression were measured by flow cytometry 72 hours post transfection. The expression of the different deletion constructs was compared to the
expression of the control RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter) construct. Assays were performed in triplicate on at least three independent
occasions. Error bars represent standard error of the mean. *p,0.05, ***p,0.001 in comparison to the unmodified control RP11-265B8::Ex5a-EK-
DsAmp (Dual Reporter) construct.
doi:10.1371/journal.pone.0022001.g002
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pGL3-Basic::5123 and pGL3-Basic::5443) as well as the reference
construct pGL3-Basic::5577 (which contains the entire conserved
region 1 sequence) all elicited a significant increase in FXN gene
expression in comparison to the pGL3-Basic::4923 construct
(which excludes conserved region 1) (Fig. 5A). These results
indicated that the regulatory element is located in the 100 bp
region between 4,923 and 5,023 bp upstream of exon 1.
To further delineate the location of the regulatory element
within conserved region 1, two further truncated constructs were
generated terminating within the 100 bp region between 4,923 bp
and 5,023 bp upstream of exon 1 of the FXN gene. These were
designated pGL3-Basic::4944 and pGL3-Basic::4961. The levels of
expression of both of the constructs were similar in the HeLa and
BE(2)-M17 cell lines. There was no significant difference between
the levels of expression elicited by the pGL3-Basic::5577 and the
pGL3-Basic::4961 constructs (Fig. 5B). However, there was a clear
reduction in expression produced by the pGL3-Basic::4944
construct; which was similar to the level of expression of the
pGL3-Basic::4923 construct. These results indicated that a
regulatory element is located in a 17 bp sequence (59 CAAATTG-
CATTCCAGAGTGT 39) between 4,944 bp and 4,961 bp
upstream of exon 1 of the FXN gene.
The 17-bp region identified via the luciferase reporter assays
was analyzed further in the RP11-265B8::Ex5a-EK-DsAmp (Dual
Reporter) assay. The 17-bp sequence located between 4,944 bp
and 4,961 bp upstream of exon 1 of the FXN gene was deleted by
homologous recombination in the dual reporter BAC construct.
The construct was analyzed in transient transfection assays in the
BHK-21 cell line. The expression of EGFP from this deletion
construct was compared to the unmodified control BAC construct.
The level of FXN gene expression produced by the BAC
construct containing the 17 bp deletion was significantly lower
(p=0.00007) than the unmodified control BAC. The level of
expression was comparable to that produced by the BAC clone
containing the entire deletion on the conserved region 1
(p=0.0001) (Fig. 6). This was further confirmed by fluorescent
microscope observation which clearly showed a reduction in
EGFP expression in cells transfected with the BAC construct
containing the 17 bp deletion compared to the control BAC, and
comparable to the BAC clone containing the entire deletion on the
conserved region 1 (Fig. S2). This result clearly indicated that the
17 bp region within conserved region 1 plays an important
regulatory role in FXN gene expression.
The identification of an Oct-1 transcription factor binding
site within the 17 bp region of conserved region 1
The Alibaba 2.1, Match 1.0 and MatInspector programs were
utilized to identify candidate regulatory elements present within
the 17 bp sequence located between 4,944 bp and 4,961 bp
upstream of exon 1 of the FXN gene. The Alibaba 2.1 program
was utilized at two stringency parameters. At the lower stringency
settings, four potential transcription factor binding sites were
identified. These were binding sites for Octamer binding protein
(Oct-1), Nuclear Factor 1 (NF-1), CCAAT/enhancer binding
protein (C/EBPbeta) and Heat Shock Transcription Factor 1
(HSF-1). At the higher stringency setting, only the Oct-1
transcription factor binding site was identified. Using the Match
1.0 program, four putative transcription factor binding sites were
identified; Oct-1, HSF-1, E-26 like protein 1 (ELK-1) and
Aspergillus nidulans developmental regulatory gene (AbaA). The
MatInspector program revealed three putative transcription factor
binding sites; Oct-1, a human muscle-specific Mt binding site and
a member of the TEA/ATTS DNA binding domain factors
(TEAD1/TEF1). The Oct-1 binding site was identified by three
independent search programs and was thus further investigated.
Figure 3. DNA fragments utilized in expression analyses. Schematic representation of PCR-amplified fragments containing the FXN promoter
and conserved regions cloned into the pGL3-Basic vector. The size of each fragment (bp) and the inclusion of particular conserved regions are shown.
The location of each of the identified conserved non-coding regions, their distance (kb) from exon 1 of the FXN gene and their coordinates (UCSC
Genome Browser, Human March 2006 assembly) are indicated. (Not to scale.)
doi:10.1371/journal.pone.0022001.g003
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ATT(A/T)GCAT [30–34]. The putative Oct-1 binding sequence
in the 17 bp region is ATTGCAT. Although this sequence differs
by one nucleotide from the consensus Oct1 binding site sequence,
it has been suggested that the missing nucleotide in the sequence
within the 17 bp region is not a crucial base for the binding of
Oct-1. Instead, the essential nucleotides for binding Oct1 are
located at the 59 end of the sequence [31].
A number of mutant constructs were generated by site directed
mutagenesis. pGL3-Basic::5023 was utilized as the starting
Figure 4. Regulatory effects of upstream conserved regions on the expression of the FXN promoter. DNA fragments containing the FXN
promoter and one or multiple upstream conserved regions were inserted into the pGL3-Basic vector. The nomenclature of the vectors is based on the
size of the cloned DNA fragments (bp) comprised of the sequence upstream of exon 1 of the FXN gene. Luciferase expression was assayed in HeLa
and BE(2)-M17 cells. The overall levels of expression were compared to the pGL3-Basic::1269 vector, the expression value of which was set as 1. Assays
were performed in triplicate on at least three independent occasions. Error bars represent standard error of the mean. *p,0.05; **p,0.01;
***p,0.001 in comparison to the control pGL3-Basic::1269 vector.
doi:10.1371/journal.pone.0022001.g004
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One derivative (designated MUT-1) was generated to contain an
extra base to exactly match the consensus Oct-1 binding site. A
second construct (MUT-2) was generated with two altered bases at
the start of the sequence (Fig. 7A). Alteration of the two bases in
MUT-2 was anticipated to inhibit Oct1 binding [31].
Transfection of each construct was performed in BE(2)-M17
cells. The expression of the pGL3-Basic::MUT1 and pGL3-
Basic::MUT2 constructs was compared to the expression of
pGL3-Basic::5577. Overexpression of the Oct-1 transcription
factor was accomplished by the co-transfection of the pCMV-
AC::Oct-1 construct that expresses human Oct-1 (Origene). As a
negative control, a construct containing only the backbone
plasmid pCMV-AC was generated by excising the Oct-1 sequence
from the original vector.
The overexpression of the Oct-1 transcription factor in the
BE(2)-M17 cell line caused a marked increase in the levels of
luciferase expression produced by the positive controls pGL3-
Basic::5577 and pGL3-Basic::5023 as well as pGL3::MUT1
(p=0.003, p=0.05 and p=0.009, respectively) (Fig. 7B). Oct-1
overexpression did not result in any significant change in the
luciferase expression of the pGL3-Basic::MUT2 vector (Fig. 7B).
These results indicated that the Oct-1 binding site had been
disrupted in the pGL3-Basic::MUT2 construct and supported the
Figure 5. Regulatory effects of conserved region 1 on the expression of the FXN promoter. DNA fragments containing the FXN promoter
and segments of conserved region 1 were inserted into the pGL3-Basic vector and luciferase expression was assayed in HeLa and BE(2)-M17 cells. The
overall levels of expression were compared to the pGL3-Basic::5577 vector, the expression value of which was set as 1. (A) Fragments terminating
5,023–5,443 bp upstream of FXN exon 1; (B) Fragments terminating 4,944–5,023 bp upstream of FXN exon 1. Assays were performed in triplicate on
at least three independent occasions. Error bars represent standard error of the mean. *p,0.05; **p,0.01; ***p,0.001 in comparison to the control
pGL3-Basic::5577 vector.
doi:10.1371/journal.pone.0022001.g005
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site are crucial for Oct1 binding [31]. This induction was also
specific to the production of Oct-1 as there was no significant
change in the expression of any construct in the presence of the
negative control pCMV-AC vector (data not shown). There was
also increased inducibility upon insertion of an extra base in
pGL3-Basic::MUT1 (4.5 fold increase) compared to pGL3-
Basic::5023 (1.7 fold increase) and pGL3-Basic::5023 (1.9 fold
increase). This is also consistent with other reported studies in
regards to the full Oct-1 binding site sequence [30–34].
Altogether, these results indicate that there is an Oct-1 binding
site within the 17 bp region that is important in FXN gene
expression and that the first two bases of the Oct1 binding site are
critical for Oct-1 binding.
Discussion
The rapid advances that have resulted from the sequencing of
the human genome and those of other species, and the
development of bioinformatics programs and matrices have
facilitated the study of gene regulation. Prior to this study,
information about the regulation of the normal human FXN gene
was limited to the regions immediately flanking the first exon of
the gene [7,9,16,35]. There was no data on the position of any
long-range, cis-acting regulatory sequences or of known transcrip-
tion factors that may control FXN gene expression. In this study, in
silico approaches were used in conjunction with different reporter
systems to identify and better understand potential long distance
cis-acting regulatory elements controlling the expression of the
human FXN gene.
The search of regulatory elements in this study was restricted to
the intergenic region upstream of exon 1 of the FXN gene to the
PRKACG gene. A detailed analysis of this 21.3 kb region revealed
the presence of eight highly conserved non-coding regions. The
eight regions are evolutionarily conserved from human to mouse
and some to even more divergent species. Each of the identified
regions is within the size range of 40–750 bp and harbor between
40% to greater than 70% homology between species. The linear
order of the identified conserved regions is maintained across the
species analyzed. These findings make the eight regions strong
candidates to contain key regulatory elements for FXN gene
expression.
The eight identified conserved sequences were analyzed via
their deletion in the context of the whole FXN locus within a dual-
reporter BAC-based assay. BACs are very useful research tools as
they can contain the entire intact locus of a gene, including
surrounding regulatory elements, thus allowing the recapitulation
of normal gene expression patterns. In addition, the positional
information of most regulatory elements required for normal gene
expression will be naturally preserved. In this approach, a reporter
gene is fused to the coding sequence of the gene of interest in the
context of its intact genomic locus and the whole construct is then
used to study gene expression in transient transfection studies. An
advantage of transient assays over the integration of BAC
constructs into the host genome is the avoidance of variation
produced by different integration sites, the influences of flanking
genomic sequences, and in differences in transgene copy number
at the site of integration.
The RP11-265B8 BAC clone utilized in this study contains the
FXN gene and significant amounts of flanking sequences, thus
making it likely to contain the intact FXN locus. This BAC
construct has also been shown to rescue the embryonic lethality of
the homozygous knockout of the mouse Fxn gene [29] indicating
that most, if not all, regulatory elements required for normal FXN
gene expression are present within this clone. This BAC clone was
also used to develop the first genomic reporter for FXN expression,
based on the targeted insertion of an EGFP cassette following the
final codon of exon 5a [28]. The DsRed-Express reporter was
introduced into the backbone of BAC clone to serve as an internal
control for transfection efficiency and vector copy number. The
presence of the two fluorescent markers enabled the monitoring of
the effects of modifications of conserved regions and permitted
correction for differing transfection efficiencies.
Modifications of each of the conserved non-coding regions
identified in silico were carried out on the dual-reporter BAC
construct. The deletion of conserved region 4 (9.5 kb upstream of
exon 1) and the deletion of conserved region 5 (12.4 kb upstream
of exon 1) resulted in an increase in FXN gene activity by 30% and
20%, respectively. It is therefore hypothesized that these regions
contain silencer elements or binding sites for repressors, which
normally serve to dampen FXN gene expression. Removal of these
sites may therefore alleviate the repression of gene expression and
result in higher levels of gene expression in individuals with
FRDA.
In contrast, the deletion of conserved region 1 (5.3 kb
upstream of exon 1) resulted in a significant reduction in FXN
Figure 6. Expression analysis of BAC dual-reporter constructs
containing deletions in conserved region 1. BHK-21 cells were
transfected with the RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter)
construct and derivatives individually containing deletions of the entire
conserved region 1 or the identified 17 bp sequence within conserved
region 1. EGFP and DsRed-Express expression were measured by flow
cytometry 72 hours post transfection. The expression of the different
deletion constructs was compared to the expression of the control
plasmid RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter) construct. Assays
were performed in triplicate on at least three independent occasions.
Error bars represent standard error of the mean. **p,0.01, ***p,0.001
in comparison to the unmodified control RP11-265B8::Ex5a-EK-DsAmp
(Dual Reporter) construct.
doi:10.1371/journal.pone.0022001.g006
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deletion of conserved region 6, located 15.5 kb upstream of exon
1, produced a similar level of reduction in gene expression to
64% of the levels of the unmodified gene. These findings indicate
that there are sequences within both of these conserved regions
that play a role in the expression of the FXN gene. The deletion of
conserved region 7 (16.5 kb upstream of exon 1) resulted in a
more modest reduction in gene expression (75% of the levels of
the unmodified gene). A possibility is that sequences in these
conserved regions act as enhancers or binding sites for
transcription factors that activate gene expression. In vertebrates,
during transcription, a number of factors are assembled together
encompassing the core promoter elements of the gene along with
other cis-regulatory sequences which include enhancer elements.
These enhancer elements could further recruit gene regulatory
proteins such as transcription factors and further increase gene
Figure 7. Regulatory effects of a putative Oct-1 binding site located within conserved region 1. (A) Two mutant constructs were
generated by site directed mutagenesis within a putative Oct-1 binding site within the identified 17 bp nucleotide sequence. MUT 1 contains one
additional extra base in the middle of the sequence and MUT 2 contains two bases substitution at the start of the sequence. (B) MUT 1 and MUT 2
were generated in the pGL3-Basic::5023 construct. Luciferase expression of the mutant constructs was analyzed following co-transfection of BE(2)-
M17 cells with pGL3-Basic derivatives and Oct-1 transcription factor-encoding plasmid pCMV-AC::Oct-1. The overall levels of expression were then
compared to the pGL3-Basic::5577 vector, the expression value of which was set as 1. Assays were performed in triplicate on at least three
independent occasions. Error bars represent standard error of the mean. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0022001.g007
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Deletion of these small regions in the assay resulted in the
possible loss of enhancer effect and the loss of binding sites for
certain transcription factors leading to an overall reduction in
FXN gene expression.
To complement the BAC reporter assays, luciferase reporter
assays were also used to study the potential role of each region.
Unlike the BAC constructs, the luciferase reporter is present on a
small, compact plasmid and is thus easier to manipulate.
Candidate regulatory sequences were cloned adjacent to the
reporter gene within a small construct. Subsequently, each
construct was transfected into cultured cells to monitor gene
expression.
Different sized fragments each containing the predicted FXN
promoter region [7] and one or more of the conserved non-coding
regions were amplified by PCR and cloned into the pGL3-Basic
vector. The smallest DNA fragment cloned contained the
1,269 bp region immediately upstream of exon 1. This fragment
included the promoter region of the FXN gene but did not contain
any of the identified conserved non-coding regions. Greene and
colleagues previously generated four constructs containing differ-
ent regions upstream of the FXN gene, ranging from 1,255 bp to
4,356 bp. Their observation in a mouse myoblast cell line showed
that no significant changes in luciferase expression was apparent
between these four constructs leading to the conclusion that there
might not be important regulatory elements located between
positions 1,255 bp and 4,356 bp upstream of exon 1 [7]. Their
results suggested that the minimal promoter activity is contained
within the first 1,255 bp immediately upstream of exon 1. In order
to replicate these findings, fragments containing 1,269 bp and
4,923 bp upstream of exon 1 were cloned into pGL3-Basic in this
study. The other inserts gradually increased in size to successively
include the identified conserved regions.
Each of the pGL3-Basic derived constructs were analyzed in
two separate cell lines, HeLa and BE(2)-M17. The parental pGL3-
Basic vector was used as the negative control while the luciferase
expression of each construct was compared to the construct
containing the 1,269 bp fragment that had been shown to contain
the minimal FXN promoter. The expression patterns produced by
the two smallest constructs containing the 1,269 bp and 4,923 bp
regions upstream of exon 1 in HeLa cells were comparable to
those reported by Greene and colleagues [7]. This was despite
differences in the cell types and species of origin between the two
studies. There was no significant difference in the relative
luciferase activity of the two constructs in HeLa cells. However,
in BE(2)-M17 cells there was a significant decrease in gene
expression observed for the construct containing the 4,923 bp
fragment compared to the minimal promoter fragment. The
4,923 bp fragment does not contain any of the identified
conserved regions, but our results indicated that there is a region
located between positions 1,269 bp and 4,923 bp upstream of the
FXN gene that elicits an inhibitory effect on gene expression in this
cell line.
A significant increase in FXN expression was observed in the
construct containing the 5,577 bp and larger inserts in both HeLa
and BE(2)-M17 cells indicating that there could be important
regulatory elements harbored at least within the 5,577 bp
fragment. Variations and fluctuations in the levels of expression
between different constructs may be due to longer regions
containing multiple regulatory elements which may enhance or
diminish gene expression. There were also differences in the
patterns of expression in the two cell lines indicating likely
differences in the specific transcription factors responsible for
modulating FXN expression in the two cell types.
The 5,577 bp fragment that elicited a marked increase in FXN
gene expression includes conserved region 1. This observation
complemented the findings from the BAC genomic reporter
assays, where the absence of this conserved non-coding region
resulted in a significant reduction in FXN gene expression. Both
sets of data strongly suggested that this region contains an
important regulatory element essential for maximal FXN gene
expression.
In order to refine the location(s) of regulatory element(s) within
this region, additional truncated fragments terminating in the
region between 4,923 bp and 5,577 bp upstream of exon 1 were
generated. The region of interest was narrowed down to a 17 bp
sequence located between 4,944 bp and 4,961 bp upstream of
exon 1 of the FXN gene. The removal of the 17 bp sequence
resulted in a reduction of gene expression of 45% and 67% in
HeLa and BE(2)-M17 cell lines, respectively. The 17 bp sequence
is located within conserved non-coding region 1 and it is sufficient
and necessary for maximal FXN gene expression.
This finding in the luciferase system was further supported by
the genomic reporter assay system. Deletion of the 17 bp region in
the context of the entire human FXN gene in the BAC reporter
clearly demonstrated a reduction in EGFP expression, by flow
cytometry analysis and fluorescent microscopy, when compared to
the control dual reporter unmodified plasmid. Furthermore, the
EGFP expression of this construct was comparable to that
observed where the entire conserved region 1 was deleted
(approximately 65% of the normal gene expression). It was
therefore evident that the absence of this region in the BAC
genomic reporter assay resulted in a decrease in FXN gene
expression and the presence of this region in the small plasmid
reporter system resulted in an increase in gene expression.
In an attempt to comprehensively identify regulatory element(s)
located within the 17 bp sequence, in silico approaches were
undertaken. A binding site for the Oct-1 transcription factor was
the most likely candidate identified by three different search tools.
Oct-1 is known to bind to an 8-bp sequence termed an octamer
motif. Mice lacking Oct-1 die during early development indicating
that the presence of this transcription factor is essential for life
[36]. Unlike other members of the POU (pituitary-specific Pit-1,
octamer-binding proteins Oct-1 and Oct-2, and neural Unc-86)
protein family, this transcription factor is expressed ubiquitously
and no specific temporal or spatial pattern is observed [37]. Oct-1
is expressed in all eukaryotic cells and regulates, either positively or
negatively, the expression of a variety of genes [38]. This ability is
attributed to its flexibility in binding DNA as a monomer,
homodimer, or heterodimer [39]. This regulatory factor has also
been shown to be important for tissue and cell-specific transcrip-
tion as well as the transcription of a number of housekeeping
genes. Oct-1 has also been shown to participate in recruiting pre-
initiation complexes in the promoter region of genes lacking a
TATA box by functionally substituting the role of transcription
binding protein (TBP) [40,41]. In the case of the FXN gene, this
finding is very relevant as there is no TATA box sequence located
within the vicinity of the FXN promoter region [7].
The candidate Oct-1 sequence in the 17 bp region (ATTG-
CAT) did not exactly match the human Oct-1 binding site
consensus sequence (ATT(A/T)GCAT) [30–34]. The missing
nucleotide has been found not to be critical for Oct-1 binding [31].
It has been found that the essential nucleotides for Oct-1 binding
are located at the 59 end of the sequence [31]. It is well accepted
that the sequence of transcription factor binding sites can often
differ in different parts of the genome.
Two constructs were generated by site directed mutagenesis.
The first construct had one base pair added to match the
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base pair alteration at the start of the sequence [31]. Upon Oct-1
transcription factor overexpression, significant increases in lucif-
erase expression were seen to be greatest with the construct
containing the one base pair addition as well as controls that
contained the 17 bp region. This increase was however not seen
with the construct containing the two base pairs modification
(pGL3-Basic::MUT2). In line with a previous study [31],
substitution of the first two base pairs resulted in the loss of Oct-
1 transcription factor inducibility.
Altogether, this result strongly suggested that the 17 bp region
delineated from conserved region 1 contains an Oct-1 binding site
and that the substitution of the first two bases within the consensus
sequence disrupted this binding. This indicates that the crucial
nucleotides for the transcription factor binding are located at the
start of the Oct-1 sequence. Furthermore, it was also shown that
the presence of an additional base within the pGL3-Basic::MUT1
construct to match the consensus Oct-1 binding site indeed
increased the luciferase reporter expression. The presence of this
extra sequence may strengthen Oct-1 transcription factor binding
in the presence of abundant transcription factor.
The findings of the current study are important and may
influence future clinical therapeutic strategies for FRDA. It is
hypothesized that any increase in frataxin levels should prove
beneficial, while a several-fold increase could be sufficient to halt
disease progression. Induction of FXN gene expression directly
addresses the primary issue of frataxin deficiency. Therapies for
hemoglobinopathies have been developed based on knowledge of
gene regulation. In b-thalassemia, where there is a disruption of b-
globin production, increasing c-globin gene expression ameliorates
disease severity [15]. As Oct-1 reduces the transcription of c-
globin, a decrease in Oct-1 binding results in an increase in c-
globin gene expression. In one study, decoy oligonucleotides
containing the Oct-1 consensus sequence were able to compete
with the endogenous c-globin cis-regulatory elements in vitro
leading to the removal of the transcription factor from the
endogenous targets and thus altering transcription of the target
gene [42]. Although this is an example of the removal a
transcription factor in order to acquire a higher level of gene
expression, it does give an insight into the possibility in modulating
the level of the Oct-1 transcription factor to influence FXN gene
expression as a potential clinical therapy for FRDA.
In conclusion, we have demonstrated that highly conserved
regions upstream of the FXN gene influence gene expression. We
have identified an Oct-1 binding site about 4.95 kb from the start
codon of the FXN gene that is necessary for normal gene
expression and whose deletion results in decreased gene
expression.
Materials and Methods
Bioinformatic analyses
Comparative and regulatory tracks available on the UCSC
Genome Browser [18,19] were examined in combination with
other external data to find regions of interest in common between
different sets of data. External data consisted of putative cis-
regulatory regions including common transcription factor binding
sites using BlastZ [27].
Bacterial strains and oligonucleotides
Escherichia coli strains used were DH10B (Invitrogen, Carlsbad,
CA) and its derivatives DY380 and EL250 [43]. All were grown in
Luria-Bertani (LB) liquid culture or on LB agar at 37uC for
DH10B and at 30uC for DY380 and EL250. Media were
supplemented with appropriate antibiotics. Sequences of oligonu-
cleotides used in this study are presented in Table S1.
Site directed mutagenesis
Site directed mutagenesis was performed using the QuikChange
Site-Directed Mutagenesis Kit (Agilent Technology, Forest Hill,
Australia) according to the manufacturer’s instructions.
Homologous recombination
Insertion of linear PCR-generated fragments into BAC DNA
was carried out by inducible homologous recombination (recom-
bineering) as previously described [43]. E. coli DY380 cells
containing a BAC vector were cultured in LB containing
appropriate antibiotics at 30uCt oa nO D 600 of 0.45. Expression
of the exo, bet and gam genes was induced by incubation at 42uC for
20 min. Cells were harvested and prepared for electroporation,
and then 0.5–2.0 mg of purified PCR product was electroporated
into electrocompetent cells. Following incubation at 30uCi n1m l
of LB for 3 h, cells were plated on LB agar containing appropriate
antibiotics and colonies allowed to form over a 24–48 h period.
Construction of a dual reporter bacterial artificial
chromosome
Homologous recombination was used to introduce a
pCMVIE—DsRed-Express—ampicillin-resistance cassette into
the backbone of the RP11-265B8::Ex5aEK BAC construct. PCR
primers EXT-BAC265-DSRED-F and EXT-DSRED-R-ADDI-
TION were used to amplify a 1.5 kb PCR product containing the
DsRed-Express gene and CMV promoter (pCMVIE) from the
pDsRed-Express-N1 plasmid (Clontech, Palo Alto, CA). The 21
nucleotides (nt) at the 39 end of EXT-BAC265-DSRED-F anneal
to a unique sequence on the pDsRed-Express-N1 plasmid and the
remaining 21 nt correspond to a sequence upstream of the
chloramphenicol-resistance gene on the RP11-265B8::Ex5aEK
BAC backbone. The 21 nt at the 39 end of EXT-DSRED-R-
ADDITION anneal to a unique sequence on pDsRed-Express-N1
and the remaining 23 nt are additional bases to facilitate the
second stage of the fusion (stitching) PCR process [44]. PCR
primers EXT-AMP-B-R-BAC265 and EXT-ADDITION-AMP-
B-F were used to amplify a 1.1 kb fragment containing the
ampicillin-resistance gene from the pBR322 plasmid (New
England Biolabs, Ipswich, MA). The 21 nt at the 39 end of
EXT-AMP-B-R-BAC265 anneal to a unique sequence on
pBR322 downstream of the ampicillin-resistance gene and the
remaining 23 nt correspond to a sequence downstream of the
chloramphenicol-resistance gene on the RP11-265B8::Ex5aEK
BAC backbone. The 22 nt at the 39 end of the EXT-ADDITION-
AMP-B-F primer anneal to a unique sequence on pBR322
between the ampicillin-resistance gene and the tetracycline-
resistance gene and the remaining 21 nt are additional bases to
facilitate the fusion PCR process. PCR products were recovered
from agarose gels and purified using a QIAquick Gel Extraction
Kit (Qiagen, Doncaster, Victoria, Australia) according to the
manufacturer’s instructions.
The two PCR products were fused into a single DNA fragment
by fusion PCR utilizing the introduced overlapping sequence and
primers EXT-BAC-DsRed-F and EXT-AMP-B-R-BAC265. The
sequence of the 2.6 kb fragment was verified by DNA sequencing
performed using Big Dye V3.1 Cycle Sequencing kit (Applied
Biosystems, Victoria, Australia) according to the manufacturer’s
recommendations.
A targeting cassette containing the pCMVIE–DsRed–ampicil-
lin-resistance sequence and incorporating homology arms for the
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EXT-TGT-R-DSAMP and EXT-TGT-F-DSAMP. The first
49 nt of the EXT-TGT-F-DSAMP primer correspond to a
sequence upstream of the chloramphenicol-resistance gene on the
RP11-265B8::Ex5aEK BAC backbone and the 21 nt at the 39
end of the primer anneal to a sequence at the 59 end of the
pCMVIE—DsRed-Express—ampicillin-resistance PCR product.
The first 47 nt of the EXT-TGT-R-DSAMP primer correspond
to a sequence downstream of the chloramphenicol-resistance
gene on the RP11-265B8::Ex5aEK BAC backbone and the
23 nt at the 39 end of the primer anneal to a sequence at the
39 end of the pCMVIE—DsRed-Express—ampicillin-resistance
PCR product.
Following the insertion of the pCMVIE—DsRed-Express—
ampicillin-resistance cassette into the RP11-265B8::Ex5aEK by
homologous recombination, the integrity of the modified con-
struct, termed RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter),
was verified by PCR, restriction digestion and DNA sequencing.
Targeted deletions in the dual reporter BAC construct
A cassette consisting of the chloramphenicol-resistance gene
flanked by FRT sites was generated by PCR using primers FRT-
CAM-F and FRT-CAM-R. FRT-CAM-F contains an EcoRI site,
35 nt corresponding to an FRT sequence and 23 nt that anneal to
a region upstream of the chloramphenicol-resistance gene in
pBACe3.6 [45]. FRT-CAM-R contains a BamHI site, an FRT site
and 24 nt homologous to a region downstream of the chloram-
phenicol-resistance gene. The PCR product was digested with
EcoRI and BamHI and cloned into pUC19. The resulting construct
was designated pUC-FRT–CAM and was used to amplify specific
targeted deletion cassettes containing the FRT–chloramphenicol-
resistance–FRT sequence. The 50 nt at the 59 end of each primer
represent the homology targeting sequences in the FXN locus and
the remainder are those used to prime amplification of the FRT–
chloramphenicol-resistance–FRT sequence. The modular struc-
ture of the PCR-amplified targeting cassette can be represented
as:[Upstream homology block]–FRT–[chloramphenicol-resistance
gene]–FRT–[Downstream homology block].
Targeted deletions were performed via induced homologous
recombination in DY380 cells containing the RP11-265B8::Ex5a-
EK-DsAmp (Dual Reporter) construct. The removal of the
chloramphenicol-resistance gene was achieved by induction of
Flp recombinase following the transformation of each construct
into EL250 cells. The integrity of each modified construct was
verified by PCR, restriction digestion and DNA sequencing.
Construction of luciferase reporter constructs
A set of progressively longer, nested DNA fragments containing
the endogenous FXN promoter and one or multiple conserved
non-coding regions was amplified by PCR. A common reverse
PCR primer (FXN-R-F) that annealed to the region just upstream
of the FXN start codon and incorporating a HindIII site was used
in all the PCR reactions. Forward primers incorporating a BglII
site were designed to anneal to different locations upstream of the
FXN gene. The RP11-265B8 BAC clone was used as a template
for PCR-amplification using the Expand Long Template PCR kit
(Roche Applied Science, Castle Hill, NSW, Australia). PCR
products were gel extracted, digested with HindIII and BglII and
cloned into the same sites of the pGL3-Basic vector (Promega,
Alexandria, NSW, Australia).
As it was not possible to amplify fragments larger than 9 kb in
sufficient quantity for cloning, an alternative strategy taking
advantage of a naturally occurring PmlI site 8.8 kb upstream of the
FXN gene was used. A reverse primer incorporating a PmlI site was
used in conjunction with forward primers incorporating a BglII
site. PCR fragments were cloned into a pGL3-Basic-derived
construct into which a 8,914 bp fragment had been cloned (Fig. 3)
following digestion with PmlI and BglII.
Tissue culture maintenance, transfection and analysis of
BAC and luciferase constructs
BHK-21 and HeLa cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Sigma, Sydney, NSW,
Australia). BE(2)-M17 cells were maintained in GIBCO-Opti-
MEM (Invitrogen, Carlsbad, CA). All media were supplemented
with 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/
ml streptomycin. Cell lines were obtained from the ATCC.
For BAC transfection procedures, BHK-21 cells were plated at
a density of 2610
5 cells per well in 6-well culture plates and
allowed to reach 80% confluency. Cells were transfected with
20 mg of purified DNA using LipofectAMINE (Invitrogen,
Carlsbad, CA), at a 4:1 lipid to DNA ratio, according to the
manufacturer’s protocol. Analysis of the cells was performed
72 hours post-transfection. Cells to be analyzed were trypsinized,
collected in 4 ml of DMEM and resuspended in 0.5 ml of clear
phosphate buffered saline (PBS) containing 1% FCS. Flow
cytometry was performed on an LSR II system (BD Biosciences,
San Jose, CA). Data was analyzed with FACSDiVa software (BD
Biosciences). Transfection of each BAC construct and flow
cytometric measurement of fluorescent reporter expression were
conducted in triplicate on three separate occasions.
Expression of EGFP from each deletion construct was
compared to the unmodified RP11-265B8::Ex5a-EK-DsAmp
(Dual Reporter). DsRed-Express expression was used as an
internal control to normalize for transfection efficiency and vector
number copy. In each case, the mean peak fluorescence (MPF)
level of EGFP representing FXN gene expression produced by
each construct was normalized against the MPF of Ds-Red-
Express. The normalized expression of each construct was then
compared to the normalized value of the unmodified RP11-
265B8::Ex5a-EK-DsAmp (Dual Reporter) which was set as 1.
For the luciferase transfection procedures, HeLa cells were
plated at a density of 2.5610
4 cells per well in 24-well culture
plates and allowed to reach 80% confluency. Cells were
transfected with purified DNA using Fugene HD (Roche, Basel,
Switzerland), at a 3.5:1 lipid to DNA ratio, according to the
manufacturer’s protocol.
BE(2)-M17 cells were plated at a density of 2.5610
4 cells per
well in 48-well culture plates and allowed to reach 80%
confluency. Cells were transfected with purified DNA using
DMRIE-C (Invitrogen, Carlsbad, CA), at a 4:1 lipid to DNA ratio,
according to the manufacturer’s protocol.
Each construct containing a firefly luciferase reporter was
transfected together with the control plasmid, pRL-SV40 that
expresses Renilla luciferase and acted as a transfection control. The
unmodified pGL3-Basic construct was included in the assay as a
negative control. Equimolar amounts of each DNA construct were
transfected taking into account the differences in size between the
constructs.
Transfection of each construct was performed in triplicate on at
least three separate occasions in both cell lines. The chemilumi-
nescent expression from both luciferase vectors was analyzed 48-
hours post transfection using the Dual-Glo Luciferase Assay
system (Promega). Cells were prepared according to the
manufacturer’s protocol. The firefly and Renilla expression were
analyzed in a FLUOstar OPTIMA microplate reader (BMG
Labtech, Cary, NC). The expression of the firefly luciferase
reporter on the pGL3-Basic derivative constructs was normalized
Regulation of FXN Gene Expression
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e22001by comparison to Renilla luciferase expression from the pRL-SV40
control vector. The expression of all pGL3-Basic derivative
constructs was then compared to the expression of the smallest
construct containing the 1,269 bp fragment (pGL3-Basic::1269)
which was set as 1.
Statistical analyses. For all transfection assays, the
experimental data is reported as the mean 6 the standard error
of the mean (S.E.M) of the triplicate assays in at least three
independent experiments. Comparisons were made between
groups of equal size by Student’s t-tests for paired data using
Excel (Microsoft, Redmond, WA). Data were considered
significantly different at p,0.05.
Transcription factor binding site programs. The
transcription factor binding site searches were performed using
the Alibaba 2.1, Match 1.0 (http://www.gene-regulation.com/
pub/programs.html) and MatInspector programs (http://www.
genomatix.de/online_help/help_matinspector/matinspector_help.
html).
Supporting Information
Figure S1 Fluorescence microscopy imaging of cells
containing BAC dual-reporter deletion constructs. BHK-
21 cells were transfected with the RP11-265B8::Ex5a-EK-DsAmp
(Dual Reporter) construct and derivatives individually containing
deletions of the identified conserved non-coding regions. Imaging
was performed 72 hours post transfection. Left image of each
panel shows red fluorescence corresponding to Ds-Red Express
expression. Right image of each panel shows green fluorescence
corresponding to FXN gene expression.
(TIF)
Figure S2 Fluorescence microscopy imaging of cells
containing the BAC dual-reporter with deletions in
conserved region 1. BHK-21 cells were transfected with the
RP11-265B8::Ex5a-EK-DsAmp (Dual Reporter) construct and
derivatives individually containing deletions of the entire con-
served region 1 or the identified 17 bp sequence within conserved
region 1. Imaging was 72 hours post transfection. Left image of
each panel obtained with transmitted light. Middle image of each
panel shows red fluorescence corresponding to Ds-Red Express
expression. Right image of each panel shows green fluorescence
corresponding to FXN gene expression.
(TIF)
Table S1 Lists of oligonucleotides used in this study.
Nucleotides shown in plain text: part of the oligonucleotide
directed to prime amplification; Underlined nucleotides; part of
homology targeting arms; Double underlined nucleotides; FRT
sequences; Underlined and italicized nucleotides: restriction
enzyme sites.
(DOC)
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